Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Wisconsin: - ThedaCare Regional Cancer Center — Appleton, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- Northwest Wisconsin Cancer Center — Ashland, Wisconsin
- Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
- Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
Phase 3 Recruiting Academic/Other
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in Wisconsin: - Langlade Hospital and Cancer Center — Antigo, Wisconsin
- Ascension Saint Elizabeth Hospital — Appleton, Wisconsin
- Ascension Southeast Wisconsin Hospital - Elmbrook Campus — Brookfield, Wisconsin
- Ascension Calumet Hospital — Chilton, Wisconsin
- Ascension Southeast Wisconsin Hospital - Franklin — Franklin, Wisconsin
Phase 3 Recruiting Network
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Sites in Wisconsin: - Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
- Marshfield Medical Center - Minocqua — Minocqua, Wisconsin
- Marshfield Medical Center-Rice Lake — Rice Lake, Wisconsin
- Marshfield Medical Center-River Region at Stevens Point — Stevens Point, Wisconsin
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Wisconsin: - Local Institution - 2145 — Appleton, Wisconsin
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Wisconsin: - University of Wisconsin, Carbone Cancer Center — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Wisconsin: - University of Wisconsin- Madison — Madison, Wisconsin
Phase 2 Recruiting Industry
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
Sponsor: NGM Biopharmaceuticals, Inc
NCT ID: NCT07033026
Sites in Wisconsin: - NGM Clinical Study Site — Appleton, Wisconsin
Phase 2 Recruiting Industry
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…
Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Phase 2 Recruiting NIH
This open-label phase II trial tests how well TPST-1495 works in reducing the number of polyps in the small bowel and colon in patients with familial adenomatous polyposis (FAP). FAP is an inherited condition in which numerous polyps (grow…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06557733
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
Phase 2 Recruiting Academic/Other
A single arm phase II study of pembrolizumab, carboplatin, paclitaxel, and radiation for the treatment of early-stage anal cancer. There are 2 treatments phases and then surveillance. The first treatment phase is the chemoradiation phase (…
Sponsor: Dustin Deming
NCT ID: NCT06493019
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Phase 2 Recruiting Academic/Other
This study is being done to see if combining liposomal irinotecan with TAS102 and bevacizumab confers clinical benefit for patients with treatment refractory metastatic colorectal cancer.
Sponsor: University of Wisconsin, Madison
NCT ID: NCT05854498
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Wisconsin: - Exelixis Clinical Site #33 — Milwaukee, Wisconsin
Phase 1 Recruiting Industry
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Sponsor: IDEAYA Biosciences
NCT ID: NCT05787587
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Phase 1 Recruiting Industry
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The s…
Sponsor: Eli Lilly and Company
NCT ID: NCT06586515
Sites in Wisconsin: - University of Wisconsin - Carbone Cancer Center — Madison, Wisconsin
Phase 1 Recruiting Industry
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is …
Sponsor: Eli Lilly and Company
NCT ID: NCT07213791
Sites in Wisconsin: - University of Wisconsin - Carbone Cancer Center — Madison, Wisconsin
Phase 1 Recruiting Industry
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT ID: NCT06625775
Sites in Wisconsin: - Wisconsin Institute for Medical Research — Madison, Wisconsin
Phase 1 Recruiting Industry
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.
Sponsor: AstraZeneca
NCT ID: NCT05877599
Sites in Wisconsin: - Research Site — Milwaukee, Wisconsin
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Wisconsin: - Langlade Hospital and Cancer Center — Antigo, Wisconsin
- ThedaCare Regional Cancer Center — Appleton, Wisconsin
- ThedaCare Regional Medical Center - Appleton — Appleton, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- Northwest Wisconsin Cancer Center — Ashland, Wisconsin
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Wisconsin: - Massive Bio SYNERGY-AI site — Milwaukee, Wisconsin
Phase 4 Recruiting Industry
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x…
Sponsor: Guerbet
NCT ID: NCT04373564
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Recruiting Industry
The primary objective of this study is to develop and train the Elephas live tumor diagnostic platform and determine the ex-vivo accuracy of the Elephas Score using in-vivo RECIST 1.1 as the reference method
Sponsor: Elephas
NCT ID: NCT05520099
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
NA Recruiting Industry
The purpose of this study is to evaluate the safety and performance of the Signia™ power handle, Signia™ circular adapter, and Signia™ Tri-Staple™ 2.0 circular reloads (hereafter referred to as Signia™ circular stapler) in patients undergo…
Sponsor: Medtronic - MITG
NCT ID: NCT07351071
Sites in Wisconsin: - SSM Health St. Mary's Hospital - Madison — Madison, Wisconsin
NA Recruiting Academic/Other
The purpose of this study is to assess the best time to deliver a message to increase physical activity and how often participants will experience a pain episode in the 24 hours following their receipt of a message to increase physical act…
Sponsor: Medical College of Wisconsin
NCT ID: NCT07227077
Sites in Wisconsin: - Froedtert Hospital — Milwaukee, Wisconsin